Certa Therapeutics’ FT011, an investigational oral therapy for systemic sclerosis (SSc), has been granted fast track designation by the U.S. Food and Drug Administration (FDA). It comes following Phase 2 clinical trial data that showed that FT011 was safe and well tolerated, and led to clinically meaningful improvements…
News
More conversations, either one on one or in groups via telephone or virtually, along with in-person household activities and conversations, were significantly associated with less loneliness during the COVID-19 pandemic among people with systemic sclerosis (SSc), a study indicates. Conversations and activities at the…
AM1476, AnaMar’s investigational anti-fibrotic medication, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating scleroderma. To get this designation, a medication must be intended to treat a life-threatening rare…
SARS-CoV-2, the virus that causes COVID-19, may accelerate the development and progression of systemic sclerosis (SSc) through fibrosis (scarring), inflammation, autoantibody production, and blood vessel damage. That’s according to a study in South Korea that shows the SARS-CoV-2 spike protein that’s required for the…
Living with scleroderma requires adapting to changes in a woman’s sense of self, but practicing gratitude and accepting change can help patients reclaim themselves, a study aiming for a “grounded theory” of identify management reports. Its scientists said these findings may lay the groundwork for future studies aiming to…
A non-invasive technique called flow-mediated dilation (FMD) could be useful for monitoring blood vessel alterations in people with systemic sclerosis (SSc) and predicting the likelihood of certain blood flow (vascular) complications, a study has found. The test findings show distinct differences between SSc patients and healthy people, and were…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the cell therapy CABA-201 for organ dysfunction in people with scleroderma. The agency also granted CABA-201 fast track status to reduce disease activity in people with dermatomyositis, another rare disorder that’s marked by muscle weakness and…
People with more circulating cholesterol — a type of lipid (fat) that plays an important role in the body — may be at a lower risk of developing systemic sclerosis (SSc), according to a study of nearly 10 million people living in South Korea. Based on these findings, researchers…
Elevated levels of the gamma-glutamyl transferase (GGT) enzyme — involved in oxidative stress, a result of insufficient antioxidant defenses against toxic free radicals — were associated with a higher risk of developing scleroderma, a large South Korean study reports. “These findings could lead to a closer monitoring for high…
Hospitalized patients with COVID-19 are more likely to have worse outcomes if they also have systemic sclerosis (SSc), a study finds. This risk was assessed by a composite score that combined several clinical measures, including in-hospital mortality, invasive mechanical ventilation to help with breathing, use of medications to raise…
Recent Posts
- Lack of small blood vessel damage patterns may predict milder SSc
- Wireless sensor may help track scleroderma skin changes at home
- New scleroderma survey seeks patient input to guide future research
- Scleroderma added to NIH project targeting autoimmune diseases
- Off-the-shelf cell therapy shows early promise as scleroderma treatment
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis
- Distinct symptom pattern found for triple-negative scleroderma patients
- Plant-based nanoparticle therapy eases skin thickening in SSc: Study
- Specialized MRI scans may catch early lung damage in scleroderma